Skip to main content
Midas Edge

Cocrystal Pharma Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitEquity
Balance as of December 31, 202310,174$10$342,288$(315,914)$26,384
Stock-based compensation--157-157
Net loss---(3,956)(3,956)
Balance as of March 31, 202410,174$10$342,445$(319,870)$22,585
Stock-based compensation--148-148
Net loss---(5,343)(5,343)
Balance as of June 30, 202410,174$10$342,593$(325,213)$17,390
Stock-based compensation--252-252
Net loss---(4,939)(4,939)
Balance as of September 30, 202410,174$10$342,845$(330,152)$12,703
Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitEquity
Balance as of December 31, 20228,143$8$337,489$(297,930)$39,567
Stock-based compensation--291-291
Net loss---(5,189)(5,189)
Balance as of March 31, 20238,143$8$337,780$(303,119)$34,669
Stock-based compensation--179-179
Sale of common stock to related entities, net of transaction costs2,03123,998-4,000
Net loss---(4,166)(4,166)
Balance as of June 30, 202310,174$10$341,957$(307,285)$34,682
Stock-based compensation--173-173
Net loss---(4,165)(4,165)
Balance as of September 30, 202310,174$10$342,130$(311,450)$30,690
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.